Pre-Market Review: ACADIA Pharma Inc., Cell Therapeutics Inc., Sarepta Therapeutics Inc., and Medivation Inc. Editor Note: For more information about this release, please scroll to bottom. PR Newswire LONDON, October 21, 2013 LONDON, October 21, 2013 /PRNewswire/ -- On Friday, October 18, 2013, all three indexes of the US equity market posted gains. The S&P 500 ended the day at 1,744.50, up 0.65%; the Dow Jones Industrial Average closed at 15,399.65, up 0.18%; and the NASDAQ Composite finished at 3,914.28, up 1.32%. Shares in the biotechnology industry mostly edged lower, even as the broader market posted gains. The major movers in the sector included ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Cell Therapeutics Inc. (NASDAQ: CTIC), Sarepta Therapeutics Inc. (NASDAQ: SRPT), and Medivation Inc. (NASDAQ: MDVN). AAAResearchReports.com initiated preliminary technical research on ACAD, CTIC, SRPT, and MDVN. These free reports are accessible by signing today at: http://www.aaaresearchreports.com/register/ On Friday, ACADIA Pharmaceuticals Inc.'s stock fell by 2.60%, even as the broader market advanced. The company's shares closed the day at $23.99, after vacillating between $23.04 and $25.17. A total of 3.10 million shares were traded, which is above the daily average volume of 2.52 million. Despite Friday's losses, the company's shares have gained 3.72% in the previous three trading sessions and 19.83% in the last three months, outperforming the S&P 500, which has gained 2.73% and 3.10% during the respective periods. Furthermore, ACADIA Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $22.90 and $14.64, respectively. The free technical analysis on ACAD is available by signing up at: http://www.AAAResearchReports.com/ACAD102113.pdf Cell Therapeutics Inc.'s stock surged on Friday, reversing most of the losses from the previous trading session. The company's shares closed the day at $1.83, up 2.23%, after fluctuating between $1.78 and $1.84 during the trading session. A total of 1.72 million shares were traded, which is below the daily average volume of 2.05 million. The company's shares have rallied 35.56% in the last one month and 74.29% in the previous three months, outperforming the S&P 500, which has gained 2.02% and 3.10% during the respective periods. Moreover, Cell Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $1.38 and $1.26, respectively. Register now to download free research on CTIC at: http://www.AAAResearchReports.com/CTIC102113.pdf Shares in Sarepta Therapeutics Inc. plummeted on Friday, extending the losses from the previous trading session. The company's shares traded between $42.42 and $46.27 before ending the day 6.58% lower at $43.02. A total of 2.72 million shares were traded, which is above the daily average volume of 2.14 million. Despite Friday's decline, Sarepta Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $40.02 and $35.50, respectively. Additionally, the company's shares have fallen by 0.65% in the last one month, compared to a gain 2.02% in the S&P 500 during the same period. A free report on SRPT can be accessed by registering at: http://www.AAAResearchReports.com/SRPT102113.pdf On Friday, Medivation Inc.'s stock also plummeted to close at $50.82, down 3.71% from the previous day's closing price of $52.78. The company's shares oscillated between $49.91 and $53.48 during the trading session. A total of 1.50 million shares were traded, which is above the daily average volume of 0.88 million. Despite Friday's pullback, the company's shares are up 1.34% in the previous three trading sessions, compared to a gain of 2.73% in the S&P 500 during the same period. Furthermore, Medivation Inc.'s stock is trading below its 50-day and 200-day moving averages of $56.83 and $53.00, respectively. Register with AAA Research Reports and download research on MDVN for free at: http://www.AAAResearchReports.com/MDVN102113.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AAAresearchreports.com SOURCE AAA Research Reports Contact: Phone #: +1(646)396-9126, Contact Name: Peter F. Jones, Email ID: email@example.com
Pre-Market Review: ACADIA Pharma Inc., Cell Therapeutics Inc., Sarepta Therapeutics Inc., and Medivation Inc.
Press spacebar to pause and continue. Press esc to stop.